Close Menu

NEW YORK ─ Luminex on Wednesday provided details of its response to a warning letter issued in late June by the US Food and Drug Administration related its Verigene SP instrument, one day after company officials said on a conference call that it was taking action to mitigate issues outlined in the letter.  

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.